Lenalidomide further enhances J6M0-mcMMAF–induced MM cell lysis. PBMCs were preincubated with or without Len (2 μM) before adding into calcein-AM–based ADCC assay with J6M0-mcMMAF or J6M0. Target cells included MM1Sluc, XG-1 (A), ANBL6 (B), CD138⁺ patient MM cells (C), and MM1S cells (D) in the presence or absence of BMSCs. J6M0-mcMMAF–induced ADCC against MM1S cells was also assayed in the supernatant from MM1S cell culture (D). (E) MM1R cells were treated with each drug, alone or together, for 3 days followed by a luminescent viability assay.